Clopidogrel 150 Mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention. Results from the Vasp-02 Randomized Study

被引：0
|
作者：
Aleil, Boris [1 ]
Jacquemin, Laurent [2 ]
De Poli, Fabien [3 ]
Zaehringer, Michel [1 ]
Collet, Jean-Philippe [4 ]
Montalescot, Gilles [4 ]
Cazenave, Jean-Pierre [5 ]
Dickele, Marie-Claude [3 ]
Monassier, Jean-Pierre [2 ]
Gachet, Christian [5 ]
机构：
[1] Clin Orangerie, Strasbourg, France
[2] Hop Emile Muller, Mulhouse, France
[3] Ctr Hosp Gen, Haguenau, France
[4] Hop La Pitie Salpetriere, Paris, France
[5] EFS Alsace, INSERM, U311, Strasbourg, France
来源：
CIRCULATION | 2008年 / 118卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S820 / S820
页数：1
相关论文
共 50 条
  • [1] Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study
    Aleil, Boris
    Jacquemin, Laurent
    De Poli, Fabien
    Zaehringer, Michel
    Collet, Jean-Philippe
    Montalescot, Gilles
    Cazenave, Jean-Pierre
    Dickele, Marie-Claude
    Monassier, Jean-Pierre
    Gachet, Christian
    JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (06) : 631 - 638
  • [2] Serum Free Triiodothyronine and the Responsiveness to Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention
    Yicong Ye
    Xiliang Zhao
    Yong Zeng
    Advances in Therapy, 2021, 38 : 3077 - 3088
  • [3] Serum Free Triiodothyronine and the Responsiveness to Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention
    Ye, Yicong
    Zhao, Xiliang
    Zeng, Yong
    ADVANCES IN THERAPY, 2021, 38 (06) : 3077 - 3088
  • [4] Cangrelor Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Results of the CHAMPION PCI Study
    Preobrazhensky, D., V
    KARDIOLOGIYA, 2010, 50 (07) : 63 - 64
  • [5] Impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions:: Results of a randomized study
    Angiolillo, Dominick J.
    Bernardo, Esther
    Costa, Marco A.
    Palazuelos, Jorge
    Desai, Blhaloo
    Weisberg, Ian
    Alfonso, Fernando
    Guzman, Luis A.
    Rozum, Liudmila
    Capranzano, Piera
    Hernandez-Antolin, Rosana
    Zenni, Martin Z.
    Macaya, Carlos
    Fernandez-Ortiz, Antonio
    Bass, Theodore A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : B85 - B85
  • [6] Effects of eptifibatide, bivalirudin and clopidogrel on platelet function in patients undergoing percutaneous coronary intervention. Final results of the DEACON study
    Saucedo, JF
    Thorn, B
    Aude, W
    Pacheco, R
    Shuler, S
    Matin, Z
    Gudapati, S
    Garza, L
    CIRCULATION, 2003, 108 (17) : 576 - 576
  • [7] Clopidogrel 150 vs. 75 mg day-1 in patients undergoing percutaneous coronary intervention: a meta-analysis
    Hao, P. P.
    Zhang, M. X.
    Li, R. J.
    Yang, J. M.
    Wang, J. L.
    Chen, Y. G.
    Zhang, Y.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (04) : 627 - 637
  • [8] Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions -: Results of a randomized study
    Angiolillo, Dominick J.
    Bernardo, Esther
    Palazuelos, Jorge
    Desai, Bhaloo
    Weisberg, Ian
    Alfonso, Fernando
    Guzman, Luis A.
    Hernandez-Antolin, Rosana
    Zenni, Martin Z.
    Macaya, Carlos
    Fernandez-Ortiz, Antonio
    Bass, Theodore A.
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (01) : 161 - 168
  • [9] Clopidogrel does not optimally inhibit platelet aggregation in patients undergoing percutaneous coronary intervention. Observations from the DEACON study
    Saucedo, JF
    Aude, W
    Garza, L
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (6A): : 10L - 11L
  • [10] Impact of Pancreatic β-Cell Function on Clopidogrel Responsiveness and Outcomes in Chinese Nondiabetic Patients Undergoing Elective Percutaneous Coronary Intervention
    Zhao, Xiliang
    Wang, Jin
    Li, Quan
    Ye, Yicong
    Zeng, Yong
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (03) : 487 - 496
12345